English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

The cyclic fungal peptide, Cyclosporine A (CsA) is one of the most potent immunosuppressants used for the management of multiple-orqan transplantation. CsA has improved early (1year) graft survival rates after kidney, heart, liver, pancreas and bone marrow transplantation and has contributed to ameliorate the treatment of autoimmune diseases refractory to conventional therapy (Goral et aI., 1997; Kagawa et aI., 2003; Ziolkowski et aI., 2003; Hesselink et aI., 2004) . The immunosuppressive effect of GsA is achieved through its impairment to interleukin-2 (IL-2) production resulting in inhibition of calcineurin that is involved in activation of T lymphocytes. Consequently, calcineurin inhibition blocks immune cell mediated reaction against the transplanted tissue (Faulds et al.,1993). However, the introduction of this drug did not translate into improved long-term graft survival. There is considerable concern that one reason for this is that on the long-term, CsA nephrotoxic effects counteract the protective role of the drug as immunosuppressant (Cattaneo et al., 2004).

EFFECT OF CYCLOSPORINE WITHDRAWAL AFTER SHORT- AND LONG·TERM CYCLOSPORINE A EXPOSURE ON THE KIDNEY OF MALE ALBINO RATS